<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35024">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01743820</url>
  </required_header>
  <id_info>
    <org_study_id>MEG001</org_study_id>
    <nct_id>NCT01743820</nct_id>
  </id_info>
  <brief_title>Phase2a Primaquine Dose Escalation Study</brief_title>
  <official_title>Phase 2a Dose Escalation Study of the Efficacy, Safety, and Pharmacokinetics of Low Dose Primaquine for Gametocytocidal Activity Against P. Falciparum in Sub-Saharan Africa and South East Asia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Malaria Research and Training Centre, Bamako, Mali</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shoklo Malaria Research, Tak, Thailand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mahidol Oxford Tropical Medicine Research Unit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wellcome Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>Mali: comités d'éthique</authority>
    <authority>Thailand: Ethical Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of low
      single-dose primaquine for gametocidal activity against P.falciparum among adult
      glucose-6-phosphate dehydrogenase (G6PD)-normal malaria patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>mosquito infectivity assessed through membrane feeding</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Baseline, Days 1, 2, 7</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>gametocyte prevalence and density</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Baseline, Hours 2, 6, 12, 24, Days 2, 3, 7, 14, 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>primaquine pharmacokinetics - area under the curve (AUC) of parent drug and metabolite</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hours 1, 2, 3, 4, 6, 8, 12, 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>asexual parasite prevalence and density</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Baseline, Hours 2, 6, 12, 24, Days 2, 3, 7, 14, 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety measurements including hemoglobin and signs of hemolysis</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Baseline, Days 1, 2, 3, 7, 14, 28</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>dihydroartemisinin-piperaquine only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>dihydroartemisinin -piperaquine (DP) only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DP and 0.125 mg/kg primaquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DP and single dose oral 0.125 mg/kg primaquine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DP and 0.5 mg/kg primaquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DP and single dose oral 0.5 mg/kg primaquine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dihydroartemisinin-piperaquine</intervention_name>
    <arm_group_label>dihydroartemisinin-piperaquine only</arm_group_label>
    <arm_group_label>DP and 0.125 mg/kg primaquine</arm_group_label>
    <arm_group_label>DP and 0.5 mg/kg primaquine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.125 mg/kg Primaquine</intervention_name>
    <arm_group_label>DP and 0.125 mg/kg primaquine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.5 mg/kg Primaquine</intervention_name>
    <arm_group_label>DP and 0.5 mg/kg primaquine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male

          -  Age &gt;= 18 years and &lt; 50 years

          -  Malaria blood thick film positive

          -  Presence of gametocytes on thick blood film

          -  Agrees to admission to study ward for 26 hours post diagnosis and available for
             follow up visits

          -  No allergies to study drugs

          -  Hemoglobin &gt;= 8 g/dl

          -  No evidence of severe or chronic disease

          -  Written, informed consent
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roland Gosling, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alassane Dicko, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Malaria Research and Training Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>François Nosten, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shoklo Malaria Research Unit</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roland Gosling, MD, PhD</last_name>
    <phone>415 597 8114</phone>
    <email>goslingr@globalhealth.ucsf.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Malaria Research and Training Centre</name>
      <address>
        <city>Bamako</city>
        <country>Mali</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alassane Dicko, MD</last_name>
      <phone>+223-6674-2296</phone>
      <email>adicko@icermali.org</email>
    </contact>
    <investigator>
      <last_name>Alassane Dicko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shoklo Malaria Research Unit</name>
      <address>
        <city>Mae Sot</city>
        <zip>63110</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francois Nosten, MD</last_name>
      <phone>+66 (0) 55 545 021</phone>
      <email>francois@tropmedres.ac</email>
    </contact>
    <investigator>
      <last_name>Francois Nosten, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mali</country>
    <country>Thailand</country>
  </location_countries>
  <reference>
    <citation>Gosling RD, Okell L, Mosha J, Chandramohan D. The role of antimalarial treatment in the elimination of malaria. Clin Microbiol Infect. 2011 Nov;17(11):1617-23. doi: 10.1111/j.1469-0691.2011.03660.x. Epub 2011 Sep 26. Review.</citation>
    <PMID>21951597</PMID>
  </reference>
  <reference>
    <citation>Baird JK, Schwartz E, Hoffman SL. Prevention and treatment of vivax malaria. Curr Infect Dis Rep. 2007 Jan;9(1):39-46.</citation>
    <PMID>17254503</PMID>
  </reference>
  <reference>
    <citation>El-Sayed B, El-Zaki SE, Babiker H, Gadalla N, Ageep T, Mansour F, Baraka O, Milligan P, Babiker A. A randomized open-label trial of artesunate- sulfadoxine-pyrimethamine with or without primaquine for elimination of sub-microscopic P. falciparum parasitaemia and gametocyte carriage in eastern Sudan. PLoS ONE. 2007 Dec 12;2(12):e1311.</citation>
    <PMID>18074034</PMID>
  </reference>
  <reference>
    <citation>Shekalaghe SA, ter Braak R, Daou M, Kavishe R, van den Bijllaardt W, van den Bosch S, Koenderink JB, Luty AJ, Whitty CJ, Drakeley C, Sauerwein RW, Bousema T. In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals. Antimicrob Agents Chemother. 2010 May;54(5):1762-8. doi: 10.1128/AAC.01135-09. Epub 2010 Mar 1.</citation>
    <PMID>20194698</PMID>
  </reference>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 8, 2013</lastchanged_date>
  <firstreceived_date>November 26, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Primaquine</mesh_term>
    <mesh_term>Dihydroquinghaosu</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
    <mesh_term>Piperaquine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
